KalVista Pharmaceuticals (NASDAQ:KALV) PT Lowered to $32.00

KalVista Pharmaceuticals (NASDAQ:KALV) had its target price reduced by stock analysts at Needham & Company LLC from $35.00 to $32.00 in a research note issued on Friday, Benzinga reports. The brokerage presently has a “buy” rating on the specialty pharmaceutical company’s stock. Needham & Company LLC’s target price suggests a potential upside of 156.00% from the company’s current price.

Separately, HC Wainwright cut their target price on KalVista Pharmaceuticals from $24.00 to $20.00 and set a “buy” rating on the stock in a research note on Friday, May 3rd.

KalVista Pharmaceuticals Trading Down 0.6 %

NASDAQ KALV opened at $12.50 on Friday. KalVista Pharmaceuticals has a 12 month low of $7.21 and a 12 month high of $16.88. The stock has a market cap of $527.38 million, a P/E ratio of -3.97 and a beta of 0.91. The stock’s fifty day moving average price is $11.84 and its 200-day moving average price is $12.44.

Insider Activity

In other news, CEO Benjamin L. Palleiko sold 21,959 shares of the company’s stock in a transaction on Monday, May 20th. The stock was sold at an average price of $11.76, for a total transaction of $258,237.84. Following the transaction, the chief executive officer now directly owns 216,387 shares of the company’s stock, valued at $2,544,711.12. The sale was disclosed in a filing with the SEC, which is available at the SEC website. In other KalVista Pharmaceuticals news, insider Edward P. Feener sold 8,088 shares of the stock in a transaction dated Monday, May 20th. The stock was sold at an average price of $11.76, for a total value of $95,114.88. Following the transaction, the insider now owns 72,858 shares of the company’s stock, valued at $856,810.08. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CEO Benjamin L. Palleiko sold 21,959 shares of the stock in a transaction dated Monday, May 20th. The shares were sold at an average price of $11.76, for a total value of $258,237.84. Following the completion of the transaction, the chief executive officer now directly owns 216,387 shares in the company, valued at approximately $2,544,711.12. The disclosure for this sale can be found here. Insiders have sold a total of 37,512 shares of company stock valued at $439,424 over the last ninety days. 12.30% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the company. Frazier Life Sciences Management L.P. lifted its holdings in KalVista Pharmaceuticals by 11.8% in the fourth quarter. Frazier Life Sciences Management L.P. now owns 3,622,294 shares of the specialty pharmaceutical company’s stock valued at $44,373,000 after acquiring an additional 383,435 shares during the period. Vanguard Group Inc. lifted its position in shares of KalVista Pharmaceuticals by 9.6% during the 3rd quarter. Vanguard Group Inc. now owns 1,732,489 shares of the specialty pharmaceutical company’s stock valued at $16,684,000 after buying an additional 151,808 shares in the last quarter. Capital World Investors purchased a new position in shares of KalVista Pharmaceuticals during the 1st quarter valued at about $17,370,000. StemPoint Capital LP lifted its position in shares of KalVista Pharmaceuticals by 174.4% during the 1st quarter. StemPoint Capital LP now owns 1,161,060 shares of the specialty pharmaceutical company’s stock valued at $13,770,000 after buying an additional 737,886 shares in the last quarter. Finally, SG Americas Securities LLC lifted its position in shares of KalVista Pharmaceuticals by 5.1% during the 4th quarter. SG Americas Securities LLC now owns 137,817 shares of the specialty pharmaceutical company’s stock valued at $1,688,000 after buying an additional 6,670 shares in the last quarter.

KalVista Pharmaceuticals Company Profile

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of small molecule protease inhibitors for diseases with unmet needs in the United States. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors.